Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, increased impulsivity and emotion dysregulation. Linkage analysis followed by fine-mapping identified variation in the gene coding for Latrophilin 3 (LPHN3), a putative adhesion-G protein-coupled receptor, as a risk factor for ADHD. In order to validate the link between LPHN3 and ADHD, and to understand the function of LPHN3 in the etiology of the disease, we examined its ortholog lphn3.1 during zebrafish development. Loss of lphn3.1 function causes a reduction and misplacement of dopaminepositive neurons in the ventral diencephalon and a hyperactive/impulsive motor phenotype. The behavioral phenotype can be rescued by the ADHD treatment drugs methylphenidate and atomoxetine. Together, our results implicate decreased Lphn3 activity in eliciting ADHD-like behavior, and demonstrate its correlated contribution to the development of the brain dopaminergic circuitry.
INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD; OMIM no. 143465) is a clinically heterogeneous neurodevelopmental disorder that is characterized by inattention, hyperactivity and increased impulsivity/emotionality. ADHD represents the most common behavioral disorder in childhood and adolescence with prevalence rates of 3--5% across different cultural settings. 1 --3 Although the substantial heritability of ADHD is documented in numerous family, twin and adoption studies, with estimates of up to 80%, both genome-wide approaches and candidate gene studies have so far failed to reliably identify and characterize ADHD-associated risk genes. 4 --8 Insights from both pharmacological studies and animal models have consistently implicated altered neurotransmission in the neurobiology of ADHD. 9 --14 The effectiveness of treating ADHD with both stimulants (for example, methylphenidate (MPH)) and noradrenaline (NA) reuptake inhibitors (for example, atomoxetine (ATO)), that interact with the dopaminergic (DA) and NA systems, and the ability of antidepressants (that target the 5-HT system) to moderate the ADHD-related emotion dysregulation have focused research onto monoaminergic signaling. 15 --19 A critical role of DA in the etiology of ADHD is also supported by genetic association studies. 20 However, the changes during neural development that lead to the symptoms of ADHD are not well understood.
Recently, Arcos-Burgos et al. 21 reported evidence of a risk haplotype in the gene coding for Latrophilin 3 (LPHN3), by linkage scan of a South American genetic isolate and subsequent finemapping of the 4q13.2 locus in several North American and European populations. Replication in a Spanish cohort of patients with adult ADHD suggested a role for LPHN3 in the persistence of the disease throughout life. 22 Furthermore, LPHN3 was also identified as one among 86 risk genes in patients with substance use disorders, a frequent comorbidity of ADHD. 23 LPHN3 is a putative adhesion-G protein-coupled receptor, but its physiological role is not well understood and an endogenous ligand has yet to be identified. 24 In recent years, the zebrafish has been established as a valid animal model for probing the genetic and developmental bases of behavior. 25 --28 In this study, we have used larval zebrafish to assess the developmental and behavioral function of Lphn3.1 activity, one of the zebrafish orthologs of LPHN3. We show that decreased Lphn3.1 activity selectively affects DA system development and triggers hyperactive/impulsive locomotion. This behavioral phenotype can be rescued by MPH and ATO, drugs that are effective in treating ADHD. These results conclusively implicate LPHN3 as one of the factors involved in the locomotor phenotype of ADHD and highlight its critical role in DA neuron development.
MATERIALS AND METHODS

In situ hybridization and histochemical methods
In situ hybridization and antibody labeling were performed on wholemount preparations (whole embryos or dissected brains) and sectioned adult brains according to standard procedures. 29 --31 Morpholino injection Lphn3 splice morpholino oligonucleotides (MO) were purchased from GeneTools LLC. Lphn3-MO1 was designed to bind the splice-donor site of exon 2, while Lphn3-MO2 blocks splicing at the exon6/intron6 boundary (Supplementary Figure S4H) . A control MO (Lphn3-CO) with 5 bp mismatches was also used. Embryos were injected with 250 mM MO (5.9 ng) at the single-cell stage and allowed to recover for 6 days with a regular day --night cycle at 28 1C before being analyzed for behavior (below). To confirm splicing defects following MO injection, 20 embryos were snap frozen in liquid nitrogen, and RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). We then used RT-PCR (carried out using the Superscriptase II kit, Invitrogen) to visualize aberrant lphn3.1 splicing in morphants, and real-time PCR (see Supplementary Methods) to quantify lphn3.1 transcripts. See Supplementary Methods for sequences of MOs and primers.
Analysis of locomotor behavior in Lphn3 morphant larvae Locomotor activity was examined at 6 days post fertilization (d.p.f.) by recording the total distance swum over a 5-min period measured using the ZebraLab software (Videotrack; ViewPoint Life Sciences, Lyon, France). Injected larvae were placed into separate wells of a 12-well plate (BD) inside a Zebrabox (ViewPoint Life Sciences) and were allowed to habituate for 5 min before recording. The distance swum was calculated by tracking the larvae for 5 min using a high-speed infrared camera with the ZebraLab software set to a detection threshold of 11, inactive/small threshold of 5 and small/large threshold of 10. To compare motor activities, the mean total distance swum was calculated for control and morphant larvae. For measurements during the night, animals that had already been measured during the day were left in the 12-well plate and were recorded for 5 min 3 h after the light was switched off in the Zebrabox. The data obtained was exported to Excel (Microsoft) for analysis. To compare the distance swum between wild-type and morphant larvae, p-values were calculated using a one-way ANOVA followed by paired t-tests with unpooled SD and the p-value adjusted according to HOLM. All data was analyzed using Excel (Microsoft) and the R Foundation statistical software package.
Drug treatment
All drug solutions were freshly prepared in embryo medium (containing 0.01% dimethyl sulfoxide) on the day of the experiment. Before drug treatment, larvae were injected with either Lphn3-CO or Lphn3-MO1 and were allowed to recover for 6 days. Morphant larvae were then incubated in either a drug solution (1, 5, 10, 15 or 20 mM ATO (Sigma-Aldrich, St Louis, MO, USA) or 8, 10, 12, 15 or 20 mM MPH (Sigma-Aldrich)) or in 0.01% dimethyl sulfoxide alone for a 1-h period. The distance swum during a 5-min time period was recorded for the different treatment groups as described above. For real-time PCR analysis of the effect of MPH and ATO treatment on lphn3.1 expression levels, larvae were treated with either 10 mM MPH or 1 mM ATO for 1 h before RNA preparation. To observe the effect of MPH or ATO treatment on DA neuron formation, larvae were treated with either 10 mM MPH or 1 mM ATO from day 0 (immediately after fertilization), on day 3 or on day 6 (for 1 h) before being fixed at 6 d.p.f.
RESULTS
Isolation and knockdown of zebrafish LPHN3 orthologs
In order to try and elucidate the endogenous function of LPHN3, we cloned and examined the corresponding gene in zebrafish. We used BLAST analysis of the zebrafish genome to identify two partial transcripts with similarity to human LPHN3 and confirmed their identity by phylogenetic analysis of Latrophilin family members from several species (Supplementary Figure S1) Figure S2A, D) , such as those labeled by elavl3 expression. 32 This pattern is maintained at 48 h.p.f. (Supplementary Figure S2B , E), whereas by 6 days post fertilization (d.p.f.) the expression of lphn3.1 becomes more restricted, with strong expression in the ventral part of the telencephalon and diencephalon and in the hindbrain as well as in the ventral spinal area (Supplementary Figure S2C, F) . At 24 h.p.f., lphn3.2 expression is seen in the ventral diencephalon (Supplementary Figure S2J , M). It expands at 48 h.p.f. to also include the telencephalon and hindbrain (in stripes of expression that appear to be complementary to those of lphn3.1), as well as at the edge of the optic tectum and the otic vesicle (Supplementary Figure  S2K, N) . By 6 d.p.f., expression of lphn3.2 appears very similar to that of lphn3.1, and is seen in the ventral part of the telencephalon, the diencephalon and the hindbrain (Supplementary Figure S2L, O) . At 30 h.p.f. lphn3.1 is coexpressed with tyrosine hydroxylase (a marker for DA neurons) in the area of the posterior tuberculum (PT)(Supplementary Figure S2X) . In order to assess the conservation of Lphn3 expression between species, we compared zebrafish lphn3.1 and mouse Lphn3 in the adult brain. Expression of lphn3.1 is seen along the telencephalic midline as well as at lower levels in the telencephalic parenchyma, the anterior thalamus, periaqueductal gray matter, the superior raphé nucleus, periventricular nucleus of the inferior hypothalamus, the cerebellum and the nucleus of the medial longitudinal fasciculus (Supplementary Figure S3A --E). This wide-spread expression profile is shared by Lphn3, the murine homolog of lphn3.1 (Supplementary Figure  S3F --I). In the adult mouse brain, Lphn3 is expressed in all layers of the cortex as well as in the dorsal and central raphé nuclei, the hippocampus and cerebellum.
This broad developmental expression provided little insight into Lphn3 function. We therefore chose to disrupt the function of lphn3.1, the LPHN3 homolog with strongest embryonic expression. Figure S4B ) and codes for a protein with a similar predicted structure as human LPHN3 (Supplementary Figure S4A) . We used two splice-blocking MO to knockdown lphn3.1 activity during development. Lphn3-MO1 targeted the exon2/intron2 boundary, and Lphn3-MO2 the exon6/intron6 boundary, regions where lphn3.1 and lphn3. 
lphn3.1 consists of 19 exons (Supplementary
Downregulation of Lphn3 function triggers locomotor hyperactivity and swimming bursts
We first investigated the consequences of decreasing Lphn3 activity on larval zebrafish behavior. Among the hallmarks of ADHD-typical syndromal dimensions, we focused on motor activity, which can be most easily evaluated in this model system. We injected Lphn3-MO1 or Lphn3-MO2 into wild-type eggs and measured locomotion 6 days later. We observed a significant increase in the distance swum by lphn3.1 morphants compared with control embryos injected with a mismatch morpholino (Lphn3-CO) ( Figure 1a ). Both MO1-and MO2-injected larvae displayed a similar increase in locomotion in multiple independent experiments (Supplementary Figure S6A and data not shown), confirming the specificity of the phenotype. We consequently restricted our analysis to Lphn3-MO1 morphant larvae.
The increased distance swum by lphn3.1 morphants (Figure 1a , Supplementary Figure S6A , B and Supplementary Video) could be caused by a decrease in the amount of time resting between swimming bouts, and/or an overall increase in swimming speed. We found no significant difference in the amount of time spent resting between Lphn3-CO-and Lphn3-MO1-injected larvae during a 5-min experiment (p ¼ 0.5 Supplementary Figure S6C) . Conversely, when excluding the resting periods, Lphn3-COinjected animals swam in average at 3.93 mm s --1 , against 6.44 mm s --1 for Lphn3-M01-injected larvae (Lphn3-CO vs Lphn3-MO1 p ¼ 0.04; Figure 1b) . Thus, the hyperactivity of lphn3.1 morphants reflected an increase in the overall speed of locomotion during periods of activity.
The symptoms of hyperactivity manifested by ADHD patients can be remarkably stable over time and may also be maintained at night. 33 --35 To determine whether the activity of lphn3.1 morphants displayed comparable properties, we first plotted the total distance swum by individual fish every 3 s during a 120-s experiment (Figure 1c) . We represented the single curves obtained by the linear equation y ¼ Sx, with a slope S of 2.8 mm s --1 in Lphn3-CO-against 6.2 mm s --1 in Lphn3-MO1 animals. These values are significantly different from each other (Linear mixed t-test po0.025) and close to the mean speed of control and morphant fish (Figure 1b) . Together, these results indicate that Lphn3.1 morphant fish display regular and stable hyperactivity. Next, to determine whether the hyperactivity of Lphn3-MO1 morphants extended into the sleeping period, we recorded the distance swum at night. As expected, both Lphn3-CO and Figure 1 . Downregulation of lphn3.1 induces hyperactivity in zebrafish larvae. (a) Mean distance swum in a 5-min time interval by 6 d.p.f. larvae injected with Lphn3-CO, Lphn3-MO1 or Lphn3-MO2. MO1-and MO2-injected larvae swam equally fast and significantly further than COinjected animals. Error bars are ±s.e.m. Lphn3-CO n ¼ 43, Lphn3-MO1 n ¼ 42, Lphn3-MO2 n ¼ 49. **po0.025, NS ¼ non significant. (b) Average swimming speed of the Lphn3-CO-and Lphn3-MO1-injected populations during a 5-min experiment, excluding the time spent resting. For Lphn3-CO, n ¼ 47 animals analyzed; for Lphn3-MO1, n ¼ 48. Lphn3-CO-injected animals swim on average 3.93 mm s --1 , whereas Lphn3-MO1 morphants swim faster, at an average speed of 6.44 mm s --1 . Error bars are ± s.e.m., *po0.05. (c) Sum over time of the distance swum (in millimeters) by Lphn3-CO-and Lphn3-MO1-injected larvae. The total distance traveled is added every 3 s during a 120-second experiment; n ¼ 10 fish for each treatment group; grey lines represent Lphn3-MO1 whereas black lines represent Lphn3-CO larvae. Lphn3-MO1 morphant fish are constantly and stably hyperactive. Linear mixed t-test po0.025. (d) Mean distance swum during 5 min by 6 d.p.f. Lphn3-CO (n ¼ 12) and Lphn3-MO1 (n ¼ 12) injected larvae during day-time (*po0.05) and night-time conditions (**po0.025). For each treatment group the same animals are analyzed at both time points. Swimming activity during the night is decreased compared with day-time (***po0.001), but night-measured Lphn3-MO1 larvae are still significantly more active than night-measured Lphn3-CO controls (**po0.025).
Lphn3-MO1 populations clearly swam less during the night. However, Lphn3-MO1 morphant larvae still displayed marked hyperactivity compared with control injected animals (Figure 1d) .
ADHD-associated increases in impulsivity, subdivided into both motor and cognitive components, 36 is seen as a fundamental trait underlying various dimensions of the behavioral impairment observed in patients. 12 When plotting the distance swum every 3 s during 90 s for individual animals, the curves for morphant fish displayed sharper peaks than those of Lphn3-CO larvae (Figure 2a , grey arrow). The individual curves for Lphn3-MO1 fish exhibit an average of 6.2 peaks compared with 2.7 peaks per individual Lphn3-CO fish (Lphn3-CO vs Lphn3-MO1 po0.001; Figure 2b) . Furthermore, the distance swum per peak was increased in morphants (Figure 2c) , whereas the time spent to swim this distance was unchanged between both treatment groups (Lphn3-CO vs Lphn3-MO1 p ¼ 0.2; Figure 2d) . Therefore, lphn3.1 morphants display more activity bursts and also accelerate significantly faster than controls (4.79 mm s --1 in Lphn3-MO1 compared with 2.14 mm s --1 in Lphn3-CO; Figure 2e ), suggesting increased motor impulsivity in their swimming behavior.
Lphn3 morphants show impaired DA system development We next aimed to determine whether any changes in neural development and/or neurotransmitter signaling correlated with the behavior of morphants. Several lines of evidence connect DA (DAergic) signaling to the etiology of ADHD. 15, 37, 38 We first used high-performance liquid chromatography to measure the concentrations of DA and its metabolite 3,4-dihydroxyphenylacetic acid in whole larvae (Supplementary Figure S7A) . Lphn3-MO1 larvae had no significant changes in either DA level or turnover compared with Lphn3-CO (Supplementary Figure S7) , suggesting that DA signaling is not globally disrupted in Lphn3-MO1. However, because this analysis would not detect subtle alterations in the formation of some DA nuclei, we examined the formation of DA neurons in the brain of 3 d.p.f. and 6 d.p.f. hyperactive lphn3.1 morphants using anti-tyrosine hydroxylase immunocytochemistry. We concentrated our analysis on the DAergic nuclei of the PT, some of which send projections to subpallial structures. Although the functional relationship of this zebrafish system with the human basal ganglia circuitry remains controversial, 39 the zebrafish PT has been implicated in the control of locomotion. 40 --42 The PT comprises 7 populations of neurons ( Figure 3k ). 43 At 3 d.p.f., we detected a global decrease in the number of PT neurons in lphn3.1 morphants (Figures 3b and d, Supplementary Figure S7B ). This included a decrease in populations 1 and 2 and a complete absence of population 3 (Figures 3a --d) . By 6 d.p.f., hyperactive Lphn3-MO1-injected larvae displayed a severe disorganization of all PT neurons (Figures 3e --j) , coupled to a reduction in the total number of both DA neurons (6 d.p.f. Lphn3-CO vs 6 d.p.f. Lphn3-MO1 po0.001, Supplementary Figure S7B ) and projections. Populations 2, 3 and 7 were almost completely absent, and populations 1 and 4/5 severely reduced (Figures 3f, h, j) . To confirm these observations, we analyzed a second DA marker, the gene coding for the DA transporter, slc6a3/dat. The number of slc6a3-positive neurons was reduced in the PT of Lphn3-MO1 compared with Lphn3-CO at both 3 d.p.f. (Supplementary Figure  S7C Locomotion is a quantitative trait, and activity levels varied within a single population of both Lphn3-CO and Lphn3-MO1 larvae (Supplementary Figure S8A) , although on average the population of Lphn3-MO1 animals were always hyperactive compared with Lphn3-CO. In order to directly examine the correlation between hyperactivity and the reduction of DA neurons, we compared the PT of individual Lphn3-CO and Lphn3-MO1 larvae distributed across the spectrum of locomotion levels. Larvae were first divided into three groups according to their behavioral phenotype (Supplementary Figure S8A) . Group 1 comprised Lphn3-MO1-injected larvae that swam further than any control larva. Larvae in groups 2 and 3 swam more or less than the mean distance measured for Lphn3-CO larvae, respectively, within the range of activity levels displayed by control larvae. We then performed anti-tyrosine hydroxylase antibody labeling and observed a gradient in the modification of PT DA neurons. Group 1 (severely hyperactive Lphn3-MO1) larvae had a strong reduction and misplacement of PT DA neurons (Supplementary Figure S8C) . Group 2 Lphn3-MO1 larvae had a mild reduction of PT neurons compared with group 2 Lphn3-CO larvae (Supplementary Figure S8D, E) , whereas the PT of group 3 Lphn3-MO1 animals was largely similar to that of group 3 Lphn-CO animals (Supplementary Figure S8F, G) . Group 2 and 3 Lphn3-CO larvae did not significantly differ from each other (Supplementary Figure S8D, F) . These observations were further validated by counting the number of cells (Supplementary Figure S8B) . Finally, DAergic projections appeared gradually but consistently reduced in morphant groups compared with controls (Supplementary Figure S8C --G) . We conclude that a severe impairment in the formation of the PT DA system does correlate with hyperactivity. However, the mild but significant reduction in DA cell numbers in group 2 Lphn3-MO1 larvae, and the consistently decreased DAergic projections in all Lphn3-MO1 groups, suggests that a threshold may exist for the number of PT DA neurons and/or projections that need to be reduced in order to trigger hyperactivity.
Other monoaminergic neurotransmitters, including NA and serotonin (5-HT), 18, 44 have been linked to ADHD, and we next analyzed hyperactive MO-injected larvae for the development of these systems. At both 3 d.p.f. and 6 d.p.f., we found that the number (Supplementary Figure S9F) and position (Supplementary Figure S9A --D) of NA neurons in the locus coeruleus 45 were similar in both Lphn3-CO-and Lphn3-MO1-injected larvae. We made an analogous observation for 5-HT neurons. In zebrafish, 5-HT neurons are found in the raphé nucleus, the ventral hypothalamus and a pretectal diencephalic cluster. 31,46 --48 We counted the number of these neurons in each cluster (Supplementary Figure  S10M) , but did not observe a significant variation in number or morphology in morphants compared with control fish (Supplementary Figure S10A --L) . Therefore, among candidate neurotransmitter pathways, only DA neurons appeared disorganized in lphn3.1 morphant larvae.
The behavioral phenotype of Lphn3 morphants can be rescued by ADHD treatment drugs One of the most effective drugs used to treat ADHD is the psychostimulant MPH, 49 an amphetamine-like compound that acts on the DA transporter. 50 MPH is believed to improve attention and cognition, leading to a secondary decrease in psychomotor activity including impulsive actions in patients. To explore whether the hyperactivity of lphn3.1 morphants could also be rescued by MPH, we treated larvae with the drug and measured locomotion. In a first dose-response study, we found that the concentration of MPH producing the largest behavioral alterations in morphants was 10 mM (Supplementary Figure S11A) . We next compared the locomotor activity of the same zebrafish larvae before and after drug treatment at the same concentration. Treatment of Lphn3-CO animals with 10 mM MPH decreased their resting time (Supplementary Figure S11C) (CO vs CO þ MPH; po0.01) but did not result in a significant change in their activity, whether measured as distance swum (Figure 4a The symptoms of ADHD in some patients can also be ameliorated by treatment with the selective NA reuptake inhibitor ATO 51 --54 that also indirectly modulates DAergic neurotransmission. 55 In a dose-response curve, we observed a general decrease in the locomotion of both Lphn3-CO and Lphn3-MO1 injected larvae upon ATO treatment. However, ATO generally had a stronger effect on morphant fish than controls (Supplementary Figure S11B ; Lphn3-CO vs Lphn3MO1; po0.001). Similar to MPH, we re-analyzed the effect of ATO treatment in a single experiment. We used 1 mM ATO, the minimum dose found to affect morphant animals (Supplementary Figure S11B) . We observed that this treatment had no significant effect on control-injected larvae (Figure 4d, Supplementary Figure S11D) . However, it rescued the hyperactivity of Lphn3-MO1-injected larvae, reducing the distance traveled to a level equivalent to that of control fish (Figure 4b ; Lphn3-CO vs MO1 þ MPH: p ¼ 0.46), similar to the effect seen in human patients. This calming effect was associated with a reduction of the mean swimming speed to the level of untreated or treated control fish (Figure 4d ) and an increase in the resting time of morphants compared with untreated Lphn3-CO and Lphn3-MO1 animals (CO vs MO þ ATO: po0.025; MO1 vs MO1 þ ATO: po0.05; Supplementary Figure S11D) . We next Individual morpholino-injected larvae exhibit motor impulsivity. (a) Lphn3-MO1 morphant fish display locomotion peaks. Distance swum (in millimeters) by Lphn3-CO-(left) and Lphn3-MO1-injected larvae (right) for five individual fish, plotted every 3 s during a 90-second experiment. On the first morphant graph the peak parameters are shown (including mean distance swum (horizontal black bar), acceleration time and height of peak (difference between the top and the base of the peak)). Peaks were defined as all acceleration events when the fish traveled 45 mm in o12 s. (b) Number of activity peaks for the Lphn3-CO-and Lphn3-MO1-injected populations during a 120-second experiment. n ¼ 10 for each group. Peak episodes occurred on average 6.2 times in morphant larvae against 2.7 times in control fish. ***po0.01. (c) Hyperactive fish cover more distance in each peak. Average height of peaks (in millimeters; the distance values indicated in panel a) is summarized and reported in this graph for the Lphn3-MO1 (average 12.86 mm) and for the Lphn3-CO larvae (average 6.58 mm). ANOVA followed by t-test n ¼ 10 ***po0.001. (d) The duration of the acceleration phase of peaks (for the time values indicated in panel a) are plotted for the morphant and control larvae. Lphn3-MO1 injected (mean duration 3.53 s) and Lphn3-CO larvae (mean duration 3.90 s) exhibit no statistical difference. ANOVA followed by t-test n ¼ 10. NS ¼ non significant. (e) Acceleration values during the peaks episodes for Lphn3-CO and Lphn3-MO1 larvae. Peak acceleration (mm s À1 ) corresponding to the ratio between the distance and time swum during the different peaks for n ¼ 10 animals. The mean acceleration in one peak is 4.76 mm s À1 for an Lphn3-MO1-and 2.14 mm s À1 for Lphn3-CO-injected larvae. ***po0.01. explored the possible mechanism by which MPH and ATO treatment could reduce the lphn3.1-linked hyperactivity. We treated wild-type larvae with either 10 mm MPH or 1 mm ATO for 1 h and measured the expression level of lphn3.1 and lphn3.2. Application of either MPH or ATO had no effect on lphn3.1 expression. Conversely, MPH mildly but significantly increased lphn3.2 expression but ATO treatment did not (Supplementary Figure S12) . We also analyzed the effect of ADHD-treatment drug application on the formation of tyrosine hydroxylase-positive PT DA neurons during development. Treatment of wild-type larvae with either 10 mm MPH or 1 mm ATO for 6 days (from 0 d.p.f.; Supplementary Figure S13B Figure S13I) . Together, these results suggest that the rescue of lphn3.1 hyperactivity by MPH and ATO probably does not occur at the level of gene expression (despite an increase in lphn3.2 expression upon ATO application), or by globally modifying the number of DA neurons in the PT.
DISCUSSION
In this study we, have analyzed the developmental and behavioral function of lphn3.1, a zebrafish homolog of the human LPHN3 gene that has been identified in ADHD patients by linkage and fine-mapping analyses. 21 The results presented here provide an essential validation of genome-wide gene identification studies and conclusively implicate LPHN3 in the etiology of ADHD. 23 The zebrafish genome contains two orthologs of LPHN3, lphn3.1 and lphn3.2, as a consequence of an extra whole-genome duplication in teleost fish. 56 The expression profiles of these two genes, appear to partially overlap during development. As a consequence, morpholino knockdown of lphn3.1 alone may cause a hypomorphic reduction of total Lphn3 protein (rather than a complete loss of function) in the brain areas where both genes are coexpressed. However, further studies of the effect of reducing both lphn3.1 and lphn3.2 will be required in order to confirm this hypothesis. Genes identified by genome-wide approaches contain polymorphisms that most likely cause a modulation of gene activity rather than a complete loss of function. 57 Our data suggests that the phenotypic dimensions of ADHD patients carrying the LPHN3 risk haplotype 21 --23 may in part be caused by an incomplete reduction of gene activity. Nevertheless, future experiments involving analyses of disease-associated LPHN3 variants identified in ADHD patients will be needed in order to directly address this issue.
Our results have several important implications. Firstly, they highlight a primary and essential role of lphn3.1 in establishing accurate DAergic signaling during development. How this specific effect is achieved despite the rather broad expression of lphn3 genes, which step(s) of DA system development are primarily under Lphn3 control, and which signaling pathway(s) depend on Lphn3 action will be important issues to address in the future. High-performance liquid chromatography analysis of the level and turnover of DA in the brain reveal no significant differences between Lphn3-MO1 and Lphn3-CO larvae. This may occur because the modification to DA neuron formation that we see in Lphn3-MO1 is restricted to one discrete cluster of neurons, alteration of which may not be sufficient to globally change DA levels. Thus, the connection between Lphn3 function and DAergic signaling needs to be studied at a higher resolution, with a focus on specific brain areas and/or projections. Lphn3 expression also appears broadly distributed in mouse but no models for Lphn3 loss-of-function have been examined so far. Latrophilin genes also have an essential role in controlling the establishment of tissue polarity during C. elegans development. 24 Thus our present data provides further evidence of the involvement of Latrophilin family adhesion-G protein-coupled receptor proteins in early development. Furthermore, as MO only provide a transient knockdown of gene activity, our study also reinforces the conclusion that ADHD is predominantly a neurodevelopmental disorder. 6, 58 Our results also demonstrate that reduction of Lphn3 function induces robust behavioral changes in larval zebrafish, with characteristics reminiscent of the hyperactivity/impulsivity phenotype observed in ADHD patients. These include stably increased locomotor behavior, night-time hyperactivity and bursts of motor impulsivity. The distinctive response of lphn3.1 morphants to ADHD-specific drugs also appears typical of ADHD behavior, with both MPH and ATO restoring morphants to control activity levels. The mechanism by which MPH and ATO rescue the locomotor behavior of lphn3.1 morphants, like in ADHD patients, remains unclear. Even though MPH causes an increased level of lphn3.2 expression following acute treatment, ATO treatment did not affect the expression of either gene (Supplementary Figure S12) . MPH and ATO treatment also had no obvious effect on the formation of PT DA neurons during development, even following chronic drug treatment (Supplementary Figure S13) . Thus, MPH and ATO are unlikely to modify ADHD-linked behavior by globally changing lphn3 gene expression levels or by normalizing the development of DA neurons. Further experiments, including highperformance liquid chromatography measures before and after MPH and ATO treatment, will be required in order to better understand the mechanism by which MPH and ATO can rescue the Lphn3-MO1 behavioral phenotype.
ADHD patients may primarily suffer from deficits in attention and concomitant failure of cognitive control, with hyperactivity and increased impulsivity occurring as a consequence. 59, 60 Inattention is complex to assess in animal models 61 --63 and we cannot currently measure it in zebrafish larvae. Nevertheless, the phenotypic expression of hyperactivity and increased impulsivity in most ADHD patients, 58, 64 and the data that we present here, strongly suggest that lphn3.1 morphant larvae are a valid model for at least some ADHD-associated locomotor endophenotypes. Finally, lphn3.1 morphants may provide a useful platform to screen for novel ADHD therapeutic strategies.
